ECSP067013A - 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 - Google Patents
2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4Info
- Publication number
- ECSP067013A ECSP067013A EC2006007013A ECSP067013A ECSP067013A EC SP067013 A ECSP067013 A EC SP067013A EC 2006007013 A EC2006007013 A EC 2006007013A EC SP067013 A ECSP067013 A EC SP067013A EC SP067013 A ECSP067013 A EC SP067013A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- cycloalkyl
- hydroxyalkyl
- quinolil
- oxazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La invención reivindica compuestos de fórmula Ien la cual es un heteroarilo de 5 miembros; X es S u O;R1 es H, alquilo, cicloalquilo, cicloalquilalquilo-, -CH2F, -CHF2, -CF3, -C(O)alquilo o -C(O)NR18R19;R3 y R4 son H, alquilo, hidroxialquilo o -C(O)Oalquilo;R5 y R6 son H, alquilo, hidroxialquilo, alcoxialquilo, mercaptoalquilo, -CH2F, -CHF2, -CF3, -C(O)OH o -C(O)Oalquilo;R7 es H, alquilo, alquenilo, hidroxialquilo, cicloalquilo, alcoxialquilo, aminoalquilo, (R17-fenil)alquilo o -CH2-C(O)-O-alquilo; y R8 comprende alquilo, heteroarilo, fenilo o cicloalquilo, o heterocicloalquilo, todos sustituidos en forma opcional, o una amida cicloalquil- o heterocicloalquil-sustituida; o R7 y R8 y el nitrógeno al cual están unidos forman conjuntamente un anillo sustituido en forma opcional; y las restantes variables son como se definen en la memoria descriptiva. También se reivindican composiciones farmacéuticas, el uso de los compuestos como inhibidores de PDE4 y combinaciones con otros activos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57226604P | 2004-05-18 | 2004-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP067013A true ECSP067013A (es) | 2006-12-29 |
Family
ID=35106691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006007013A ECSP067013A (es) | 2004-05-18 | 2006-11-17 | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 |
Country Status (20)
Country | Link |
---|---|
US (1) | US7511062B2 (es) |
EP (1) | EP1758883B1 (es) |
JP (1) | JP4584990B2 (es) |
KR (1) | KR100907354B1 (es) |
CN (1) | CN1984901B (es) |
AR (1) | AR055192A1 (es) |
AT (1) | ATE531705T1 (es) |
AU (1) | AU2005247906B2 (es) |
BR (1) | BRPI0511295A (es) |
CA (1) | CA2565599C (es) |
EC (1) | ECSP067013A (es) |
IL (1) | IL179280A (es) |
MX (1) | MXPA06013414A (es) |
NO (1) | NO20065830L (es) |
NZ (1) | NZ551017A (es) |
PE (1) | PE20060241A1 (es) |
RU (1) | RU2417993C9 (es) |
TW (1) | TWI286475B (es) |
WO (1) | WO2005116009A1 (es) |
ZA (1) | ZA200609277B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8145182B2 (en) * | 2004-05-07 | 2012-03-27 | Interdigital Technology Corporation | Supporting emergency calls on a wireless local area network |
US8682279B2 (en) | 2004-05-07 | 2014-03-25 | Interdigital Technology Corporation | Supporting emergency calls on a wireless local area network |
KR101122359B1 (ko) | 2004-05-07 | 2012-03-23 | 인터디지탈 테크날러지 코포레이션 | 무선 근거리 통신망의 긴급 호 지원 |
EP2484382A1 (en) * | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
WO2007078990A2 (en) * | 2005-12-23 | 2007-07-12 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
BRPI0707091B8 (pt) | 2006-03-10 | 2018-02-14 | Nissan Chemical Ind Ltd | composto de isoxalina e benzaldoxima substituído ou um sal do mesmo; pesticida, agroquímico, endo- ou ecto-parasiticidapara mamíferos ou pássaros, inseticida e acaricida contendo como um ou mais ingredientes ativos selecionados a partir do composto de isoxalina substituído e o sal do mesmo |
UA91129C2 (ru) * | 2006-05-09 | 2010-06-25 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит |
EP2038279A2 (en) * | 2006-06-06 | 2009-03-25 | Avigen, Inc. | Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use |
JP5280357B2 (ja) * | 2006-07-07 | 2013-09-04 | スティーブン・ピー・ガベック | Pde4の二環式ヘテロアリール阻害剤 |
US8138205B2 (en) * | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
BRPI0712915A2 (pt) * | 2006-07-11 | 2012-10-09 | Schering Corp | sal de xinafoato de um composto de 5-oxazal-2-il-quinolina substituìdo |
ITMI20061581A1 (it) * | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
EP2385050A1 (en) * | 2006-08-14 | 2011-11-09 | Schering Corporation | A process for preparing a substituted oxazole |
CN101522671A (zh) * | 2006-08-14 | 2009-09-02 | 先灵公司 | 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类,及其制备方法 |
US7902157B2 (en) | 2006-09-15 | 2011-03-08 | Schering Corporation | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
CA2663501A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Treating pain, diabetes, and disorders of lipid metabolism |
WO2008033456A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism |
AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
JP2008260691A (ja) * | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
JP4986927B2 (ja) * | 2007-05-14 | 2012-07-25 | 大塚製薬株式会社 | 医薬 |
WO2008157205A2 (en) * | 2007-06-15 | 2008-12-24 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
CA2692776A1 (en) * | 2007-07-10 | 2009-01-15 | Schering Corporation | Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof |
WO2009009003A1 (en) * | 2007-07-10 | 2009-01-15 | Schering Corporation | Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof |
GB2451629A (en) * | 2007-08-06 | 2009-02-11 | Univ Sheffield | 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones |
RU2010128543A (ru) | 2007-12-11 | 2012-01-20 | Сайтопатфайндер, Инк. (Jp) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
ES2454366T3 (es) * | 2008-02-22 | 2014-04-10 | Neurotune Ag | Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
TWI396689B (zh) * | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
JP5476895B2 (ja) | 2008-12-17 | 2014-04-23 | セントラル硝子株式会社 | ヒドロキシル基置換生成物の製造方法 |
US8809538B2 (en) | 2009-01-12 | 2014-08-19 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
SG10201405568UA (en) * | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
US8435976B2 (en) * | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
JP5709101B2 (ja) * | 2010-09-01 | 2015-04-30 | 東レ・ファインケミカル株式会社 | ヒドロキシプロリン誘導体の製造法 |
WO2012031383A1 (zh) | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
WO2012072512A1 (en) | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
CN102408433B (zh) * | 2011-10-20 | 2014-04-09 | 天津药物研究院 | 含嘧啶的肟类化合物、其制备方法和用途 |
US8530461B2 (en) * | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
CN104379568A (zh) | 2012-04-24 | 2015-02-25 | 中外制药株式会社 | 喹唑啉二酮衍生物 |
US9695118B2 (en) * | 2012-04-24 | 2017-07-04 | Chugai Seiyaku Kabushiki Kaisha | Benzamide derivative |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
CA2905751A1 (en) | 2013-03-13 | 2014-10-09 | Forma Therapeutics, Inc. | Novel compounds and compositions for inhibition of fasn |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
WO2014151959A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
EP2968304B1 (en) | 2013-03-14 | 2018-10-10 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
EP3061749B1 (en) | 2013-10-23 | 2019-02-27 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
CN105085429B (zh) * | 2014-04-25 | 2019-12-10 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
WO2015168286A1 (en) | 2014-04-30 | 2015-11-05 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparaiton and use |
GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
JP2018016544A (ja) * | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ[2.2.2]オクタン誘導体 |
CN104829492A (zh) * | 2015-05-06 | 2015-08-12 | 河北工业大学 | 一种反式N-Boc-1,3-环丁二胺的制备方法 |
CN106279138B (zh) * | 2015-12-29 | 2019-03-01 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物中的应用 |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
US11040945B2 (en) | 2017-12-06 | 2021-06-22 | Lin Bioscience Pty Ltd. | Tubulin inhibitors |
AU2019215799B2 (en) * | 2018-02-01 | 2022-04-14 | The University Of Sydney | Anti-cancer compounds |
KR20200004573A (ko) * | 2018-07-04 | 2020-01-14 | 고려대학교 세종산학협력단 | 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물 |
EP3808747A4 (en) * | 2018-09-13 | 2022-03-09 | Kissei Pharmaceutical Co., Ltd. | IMIDAZOPYRIDINONE COMPOUND |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
WO2022156727A1 (zh) | 2021-01-21 | 2022-07-28 | 浙江养生堂天然药物研究所有限公司 | 治疗肿瘤的组合物及方法 |
US11787805B2 (en) * | 2022-01-28 | 2023-10-17 | BioAge Labs, Inc. | N-oxide inhibitors of NLRP3 inflammasome |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0912519A1 (en) | 1996-05-20 | 1999-05-06 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
NZ332341A (en) | 1996-05-20 | 2000-05-26 | Darwin Discovery Ltd | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
US6069151A (en) * | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
EP0946541B1 (en) * | 1996-11-06 | 2003-07-30 | Darwin Discovery Limited | Quinolines and their therapeutic use |
AU4038000A (en) | 1999-03-29 | 2000-10-16 | Neurogen Corporation | 4-substituted quinoline derivatives as gaba receptor ligands |
US6569885B1 (en) * | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
GB0003254D0 (en) | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
WO2002014291A1 (en) | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
US7078422B2 (en) | 2001-03-23 | 2006-07-18 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
BRPI0712915A2 (pt) * | 2006-07-11 | 2012-10-09 | Schering Corp | sal de xinafoato de um composto de 5-oxazal-2-il-quinolina substituìdo |
-
2005
- 2005-05-16 MX MXPA06013414A patent/MXPA06013414A/es active IP Right Grant
- 2005-05-16 CN CN2005800236668A patent/CN1984901B/zh not_active Expired - Fee Related
- 2005-05-16 CA CA2565599A patent/CA2565599C/en not_active Expired - Fee Related
- 2005-05-16 BR BRPI0511295-8A patent/BRPI0511295A/pt not_active IP Right Cessation
- 2005-05-16 RU RU2006144709/04A patent/RU2417993C9/ru not_active IP Right Cessation
- 2005-05-16 KR KR1020067024186A patent/KR100907354B1/ko not_active IP Right Cessation
- 2005-05-16 JP JP2007513471A patent/JP4584990B2/ja not_active Expired - Fee Related
- 2005-05-16 WO PCT/US2005/017134 patent/WO2005116009A1/en active Application Filing
- 2005-05-16 NZ NZ551017A patent/NZ551017A/en unknown
- 2005-05-16 AT AT05750076T patent/ATE531705T1/de active
- 2005-05-16 PE PE2005000540A patent/PE20060241A1/es not_active Application Discontinuation
- 2005-05-16 US US11/130,359 patent/US7511062B2/en not_active Expired - Fee Related
- 2005-05-16 AU AU2005247906A patent/AU2005247906B2/en not_active Ceased
- 2005-05-16 EP EP05750076A patent/EP1758883B1/en active Active
- 2005-05-17 TW TW094115924A patent/TWI286475B/zh not_active IP Right Cessation
- 2005-05-17 AR ARP050102012A patent/AR055192A1/es not_active Application Discontinuation
-
2006
- 2006-11-07 ZA ZA200609277A patent/ZA200609277B/en unknown
- 2006-11-14 IL IL179280A patent/IL179280A/en not_active IP Right Cessation
- 2006-11-17 EC EC2006007013A patent/ECSP067013A/es unknown
- 2006-12-15 NO NO20065830A patent/NO20065830L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2565599C (en) | 2012-07-31 |
AR055192A1 (es) | 2007-08-08 |
CN1984901A (zh) | 2007-06-20 |
IL179280A0 (en) | 2007-03-08 |
CA2565599A1 (en) | 2005-12-08 |
JP2007537300A (ja) | 2007-12-20 |
NZ551017A (en) | 2010-11-26 |
IL179280A (en) | 2011-07-31 |
BRPI0511295A (pt) | 2007-12-04 |
ZA200609277B (en) | 2008-06-25 |
TW200602056A (en) | 2006-01-16 |
EP1758883B1 (en) | 2011-11-02 |
US7511062B2 (en) | 2009-03-31 |
WO2005116009A1 (en) | 2005-12-08 |
CN1984901B (zh) | 2011-02-09 |
AU2005247906B2 (en) | 2011-08-25 |
PE20060241A1 (es) | 2006-04-01 |
RU2006144709A (ru) | 2008-06-27 |
US20060106062A1 (en) | 2006-05-18 |
EP1758883A1 (en) | 2007-03-07 |
KR100907354B1 (ko) | 2009-07-10 |
RU2417993C9 (ru) | 2011-10-10 |
AU2005247906A1 (en) | 2005-12-08 |
JP4584990B2 (ja) | 2010-11-24 |
RU2417993C2 (ru) | 2011-05-10 |
MXPA06013414A (es) | 2007-01-23 |
KR20070013306A (ko) | 2007-01-30 |
ATE531705T1 (de) | 2011-11-15 |
TWI286475B (en) | 2007-09-11 |
NO20065830L (no) | 2007-02-16 |
WO2005116009B1 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
CY1119101T1 (el) | Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR071644A1 (es) | Plaguicidas mesoionicos | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
ECSP12006640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
PE20090042A1 (es) | Analogos de ciclopamina | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
BRPI0508966A (pt) | composto, composição farmacêutica, e, uso de um composto | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
ES2531256T3 (es) | Amidas fungicidas | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR059925A1 (es) | Formulaciones | |
PE20140961A1 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
DE602006019221D1 (de) | Von dopamin-d3-rezeptoren |